SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY
Stefan Schreiber 1
Mamoru Watanabe 2
Chohee Yun 3
Yan Zhou 3
Sally Zhao 3
Jeremy Hsieh 3
Ulrik Moerch 4
Gerhard Rogler 5
Edward V Loftus Jr 6
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 Tokyo Medical and Dental University, Tokyo, Japan
3 Gilead Sciences, Inc., Foster City, United States
4 Gilead Sciences, Inc., Copenhagen, Denmark
5 University of Zurich, Zurich, Switzerland
6 Mayo Clinic College of Medicine, Rochester, Minnesota, United States
Topic
IBD, Paediatrics
Session
IBD epidemiology and drug safety
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]